Salín-Pascual RJ

Language: Spanish
References: 25
Page: 604-610
PDF size: 84.23 Kb.

ABSTRACT

Insomnia could be a symptom if it is part of other diseases, or a manifestation by itself that precede major depression as well as anxiety. As a secondary problem psychiatric disorders are the leading cause followed by neurological and internal medicine problems. Insomnia could be a problem for to star the sleep episode (more than 30 minutes); several awakenings during night with at least one of them more than 20 minutes, or early morning awakening (one hour in advance from the usual time). Primary insomnia is an entity that has been recognized recently as possible, and that could be in fact a prodormal like manifestation of other major psychiatric problems like major depression and anxiety. Physiopathologies of primary insomnia start to be understood as a permanent waking state or hyperarrousal state. Also has been compared as if the subject received a continuous infusion of caffeine (caffeine-like state). There are several medications of different groups base on their pharmacodinamics: benzodiazepines, hypnotic non-benzodiazepines, sedative antidepressants as well as antipsychotics. All of them are tools for to deal with different medical issues, so the main goal as physicians is to reach a diagnostic entity. It in obvious that non-pharmacological strategies like sleep hygiene, cognitive-behavioral psychotherapy and relaxation techniques are as useful as medications. A poor sleep quality is linked to a poor life quality and very often to some psychiatric and medical problems.

REFERENCES

1. Billiard M, Bentley A. Is insomnia best categorized as a symptom or a disease? Sleep Medicine 2004; 5: S35-S40.

2. Drake CL, Roehrs T, Roth T. Insomnia causes consequences, and therapeutics: An overview. Depression and Anxiety 2003; 18: 163-76.

3. Daly JW, Fedholm BB. An atypical drug of dependence. Drug Alcohol Depend 1998; 51: 199-206.

4. National Institute of Health. Consensus Development Conference. Drugs and Insomnia: the use of medication to promote sleep. JAMA 1984; 251: 2410-14.

5. National Institute of Health. Consensus Development Conference. The treatment of sleep disorders of older people. Sleep 1991; 14: 169-77.

6. Breslau N, Roth T, Rosenthal L, Andresky P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996; 39: 411-18.

7. Moul D, Germain A, Cashmere DJ, Miewald JM, Buysse DJ. Sleep onset process abnormalities in primary insomnia. Sleep 2004; 27: 274.

8. Edinger JD, Means MK. Overview of insomnia: Definitions, epidemiology, differential diagnosis, and assessment. In: Kryeger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. New York: Elsevier Saunder; 2005, p. 702-13.

9. Borbely AA. A two process model of sleep regulation. Hum Neurobiol 1982; 1: 195-204.

10. Rajkowski J, Kubiak P, Aston-Jones G. Locus coeruleus activity in monkey: phasic and tonic changes are associated with altered vigilance. Brain Res Bull 1994; 607-16.

11. Salin-Pascual RJ. Bases bioquímicas y farmacológicas de la neuropsiquiatría. 1st ed. México: McGraw-Hill Interamericana; 1997.

12. Salin-Pascual RJ. Hypocretins and adenosine in the regulation of sleep. Revista de Neurología 2004; 39: 354-8.

13. Salin-Pascual RJ, Gerashchenko D, Blanco-Centurion C, Shiromani PJ. Hypothalamic regulation of sleep. Neuropsychopharmacology 2001; 25: S21-S27.

14. Hollbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162: 225-33.

15. Salin-Pascual RJ. Tratamiento de las alteraciones del sueño. In: Salin-Pascual RJ, editor. Trastornos del Dormir. México: McGraw-Hill Interamericana; 2000, p. 211-20.

16. Perlis ML, McCall W, Andrew K, Walsh JK. No evidence of tolerance with long-term non-nightly zolpidem administration in patients with primary insomnia. Sleep 2004; 27: 254.

17. Perlis ML, McCall W, Krystal A, Walsh JK. Non-nightly administration of zolpidein for treatment of primary insomnia does not lead to dose escalation. Sleep 2004; 27: 258-9.

18. Semler CN, Harvey AG. An investigation of monitoring for sleep-related threat in primary insomnia. Behaviour Research and Therapy 2004; 42: 1403-20.

19. Swainston Harrison T, Keating GM. Zolpidem: a review of its use in the management of insomnia. CNS Drugs 2005; 19: 65-89.

20. Walsh JK, Roth T, Randazzo A, Erman M, Jamieson A, Scharf M, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23: 1087-96.

21. O’Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005; 66: 28-33.

22. Winokur A, DeMartinis NA3, McNally DP, Gary EM, Cormier JL, Gary KA. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2005; 64: 1224-9.

23. Mendelson W. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66: 469-76.

24. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Laurrabaquio MR. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999; 46: 141-3.

25. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Rosas M, Brunner E. Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients. Rev Invest Clin 2004; 56: 345-50.